Company intelligence / Profile preview
GliaPharm
Geneva, Switzerlandgliapharm.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate GP-119 has shown to be safe, penetrate the brain at active concentrations after oral administration, enhance brain energy metabolism in preclinical models, and restore memory in mouse models of memory impairments linked to hypometabolism. Currently progressing towards IND-enabling studies with ADDF support[4].
- Therapeutic areas
- PsychiatryRare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
UMC UtrechtAlzheimer's Drug Discovery Foundation (ADDF)Evotec
Beyond the preview
Go deeper on GliaPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GliaPharm.